{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:33:45Z","timestamp":1793738025350,"version":"4.6.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100009560","name":"Uniklinikum Giessen und Marburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009560","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014584","name":"Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014584","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s40263-023-01039-y","type":"journal-article","created":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T19:01:25Z","timestamp":1696273285000},"page":"929-936","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Third-Generation Antiseizure Medication in the Treatment of Benzodiazepine-Refractory Status Epilepticus in Poststroke Epilepsy: A Retrospective Observational Register-Based Study"],"prefix":"10.1007","volume":"37","clinical-trial-number":[{"clinical-trial-number":"nct05267405","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9854-4038","authenticated-orcid":false,"given":"Yaroslav","family":"Winter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Sandner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Vieth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Gonzalez-Escamilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian V.","family":"Stuckrad-Barre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergiu","family":"Groppa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,2]]},"reference":[{"key":"1039_CR1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.neuint.2017.02.002","volume":"107","author":"T Tanaka","year":"2017","unstructured":"Tanaka T, Ihara M. Post-stroke epilepsy. Neurochem Int. 2017;107:219\u201328.","journal-title":"Neurochem Int"},{"issue":"8","key":"1039_CR2","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1007\/s00115-008-2505-3","volume":"79","author":"Y Winter","year":"2008","unstructured":"Winter Y, Wolfram C, Sch\u00f6ffski O, Dodel RC, Back T. Long-term disease-related costs 4 years after stroke or TIA in Germany. Nervenarzt. 2008;79(8):918\u201320 (22\u20134, 26).","journal-title":"Nervenarzt."},{"issue":"4","key":"1039_CR3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1468-1331.2004.00992.x","volume":"12","author":"L Forsgren","year":"2005","unstructured":"Forsgren L, Beghi E, Oun A, Sillanp\u00e4\u00e4 M. The epidemiology of epilepsy in Europe: a systematic review. Eur J Neurol. 2005;12(4):245\u201353.","journal-title":"Eur J Neurol"},{"issue":"4","key":"1039_CR4","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1528-1157.1986.tb03567.x","volume":"27","author":"K L\u00fchdorf","year":"1986","unstructured":"L\u00fchdorf K, Jensen LK, Plesner AM. Etiology of seizures in the elderly. Epilepsia. 1986;27(4):458\u201363.","journal-title":"Epilepsia"},{"issue":"6","key":"1039_CR5","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1179\/1074935715Z.00000000062","volume":"22","author":"S Zou","year":"2015","unstructured":"Zou S, Wu X, Zhu B, Yu J, Yang B, Shi J. The pooled incidence of post-stroke seizure in 102 008 patients. Top Stroke Rehabil. 2015;22(6):460\u20137.","journal-title":"Top Stroke Rehabil"},{"issue":"2","key":"1039_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1590\/0004-282X20140217","volume":"73","author":"TR Assis","year":"2015","unstructured":"Assis TR, Bacellar A, Costa G, Nascimento OJ. Etiological prevalence of epilepsy and epileptic seizures in hospitalized elderly in a Brazilian tertiary center, Salvador. Brazil Arq Neuropsiquiatr. 2015;73(2):83\u20139.","journal-title":"Brazil. Arq Neuropsiquiatr."},{"issue":"7528","key":"1039_CR7","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1136\/bmj.331.7528.1317","volume":"331","author":"MJ Brodie","year":"2005","unstructured":"Brodie MJ, Kwan P. Epilepsy in elderly people. BMJ. 2005;331(7528):1317\u201322.","journal-title":"BMJ"},{"issue":"11","key":"1039_CR8","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1001\/archneur.57.11.1617","volume":"57","author":"CF Bladin","year":"2000","unstructured":"Bladin CF, Alexandrov AV, Bellavance A, Bornstein N, Chambers B, Cot\u00e9 R, et al. Seizures after stroke: a prospective multicenter study. Arch Neurol. 2000;57(11):1617\u201322.","journal-title":"Arch Neurol"},{"issue":"5","key":"1039_CR9","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/j.1528-1167.2008.01945.x","volume":"50","author":"DC Hesdorffer","year":"2009","unstructured":"Hesdorffer DC, Benn EK, Cascino GD, Hauser WA. Is a first acute symptomatic seizure epilepsy? Mortality and risk for recurrent seizure. Epilepsia. 2009;50(5):1102\u20138.","journal-title":"Epilepsia"},{"issue":"8","key":"1039_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0136200","volume":"10","author":"T Tanaka","year":"2015","unstructured":"Tanaka T, Yamagami H, Ihara M, Motoyama R, Fukuma K, Miyagi T, et al. Seizure outcomes and predictors of recurrent post-stroke seizure: a retrospective observational cohort study. PLoS ONE. 2015;10(8): e0136200.","journal-title":"PLoS ONE"},{"issue":"4","key":"1039_CR11","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/epi.12550","volume":"55","author":"RS Fisher","year":"2014","unstructured":"Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475\u201382.","journal-title":"Epilepsia"},{"issue":"5","key":"1039_CR12","first-page":"CD007144","volume":"2016","author":"MA Leone","year":"2016","unstructured":"Leone MA, Giussani G, Nolan SJ, Marson AG, Beghi E. Immediate antiepileptic drug treatment, versus placebo, deferred, or no treatment for first unprovoked seizure. Cochrane Database Syst Rev. 2016;2016(5):CD007144.","journal-title":"Cochrane Database Syst Rev."},{"issue":"2","key":"1039_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S1474-4422(17)30404-0","volume":"17","author":"M Galovic","year":"2018","unstructured":"Galovic M, D\u00f6hler N, Erd\u00e9lyi-Canavese B, Felbecker A, Siebel P, Conrad J, et al. Prediction of late seizures after ischaemic stroke with a novel prognostic model (the SeLECT score): a multivariable prediction model development and validation study. Lancet Neurol. 2018;17(2):143\u201352.","journal-title":"Lancet Neurol"},{"issue":"4","key":"1039_CR14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40266-021-00837-7","volume":"38","author":"M Galovic","year":"2021","unstructured":"Galovic M, Ferreira-Atuesta C, Abraira L, D\u00f6hler N, Sinka L, Brigo F, et al. Seizures and epilepsy after stroke: epidemiology, biomarkers and management. Drugs Aging. 2021;38(4):285\u201399.","journal-title":"Drugs Aging"},{"issue":"1","key":"1039_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s13760-021-01742-x","volume":"123","author":"A Ouerdiene","year":"2023","unstructured":"Ouerdiene A, Messelmani M, Derbali H, Mansour M, Zaouali J, Mrissa N, et al. Post-stroke seizures: risk factors and management after ischemic stroke. Acta Neurol Belg. 2023;123(1):145\u201352.","journal-title":"Acta Neurol Belg."},{"issue":"4","key":"1039_CR16","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3390\/brainsci11040418","volume":"11","author":"S Lattanzi","year":"2021","unstructured":"Lattanzi S, Rinaldi C, Cagnetti C, Foschi N, Norata D, Broggi S, et al. Predictors of pharmaco-resistance in patients with post-stroke epilepsy. Brain Sci. 2021;11(4):418.","journal-title":"Brain Sci"},{"key":"1039_CR17","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.yebeh.2017.12.037","volume":"80","author":"Y Winter","year":"2018","unstructured":"Winter Y, Daneshkhah N, Galland N, Kotulla I, Kr\u00fcger A, Groppa S. Health-related quality of life in patients with poststroke epilepsy. Epilepsy Behav. 2018;80:303\u20136.","journal-title":"Epilepsy Behav"},{"issue":"6","key":"1039_CR18","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s40263-022-00922-4","volume":"36","author":"NA Shlobin","year":"2022","unstructured":"Shlobin NA, Sander JW. Current principles in the management of drug-resistant epilepsy. CNS Drugs. 2022;36(6):555\u201368.","journal-title":"CNS Drugs"},{"issue":"2","key":"1039_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1001\/jamaneurol.2021.4584","volume":"79","author":"D Larsson","year":"2022","unstructured":"Larsson D, Baftiu A, Johannessen Landmark C, von Euler M, Kumlien E, \u00c5sberg S, et al. Association between antiseizure drug monotherapy and mortality for patients with poststroke epilepsy. JAMA Neurol. 2022;79(2):169\u201375.","journal-title":"JAMA Neurol"},{"issue":"2","key":"1039_CR20","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1212\/WNL.54.2.350","volume":"54","author":"L Rumbach","year":"2000","unstructured":"Rumbach L, Sablot D, Berger E, Tatu L, Vuillier F, Moulin T. Status epilepticus in stroke: report on a hospital-based stroke cohort. Neurology. 2000;54(2):350\u20134.","journal-title":"Neurology"},{"issue":"10","key":"1039_CR21","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1007\/s00115-020-01036-2","volume":"92","author":"F Rosenow","year":"2021","unstructured":"Rosenow F, Weber J. S2k guidelines: status epilepticus in adulthood: guidelines of the German Society for Neurology. Nervenarzt. 2021;92(10):1002\u201330.","journal-title":"Nervenarzt"},{"key":"1039_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.seizure.2022.07.003","volume":"100","author":"Y Winter","year":"2022","unstructured":"Winter Y, Uphaus T, Sandner K, Klimpe S, Stuckrad-Barre SV, Groppa S. Efficacy and safety of antiseizure medication in post-stroke epilepsy. Seizure. 2022;100:109\u201314.","journal-title":"Seizure."},{"key":"1039_CR23","doi-asserted-by":"publisher","first-page":"175628561774208","DOI":"10.1177\/1756285617742081","volume":"11","author":"LJ Stephen","year":"2018","unstructured":"Stephen LJ, Brodie MJ. Brivaracetam: a novel antiepileptic drug for focal-onset seizures. Ther Adv Neurol Disord. 2018;11:1756285617742081.","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"1039_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.1527-3458.2007.00001.x","volume":"13","author":"BK Beyreuther","year":"2007","unstructured":"Beyreuther BK, Freitag J, Heers C, Krebsf\u00e4nger N, Scharfenecker U, St\u00f6hr T. Lacosamide: a review of preclinical properties. CNS Drug Rev. 2007;13(1):21\u201342.","journal-title":"CNS Drug Rev"},{"key":"1039_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.seizure.2015.09.012","volume":"32","author":"AC Jongeling","year":"2015","unstructured":"Jongeling AC, Richins RJ, Bazil CW. Safety and tolerability of an oral zonisamide loading dose. Seizure. 2015;32:69\u201371.","journal-title":"Seizure."},{"issue":"10","key":"1039_CR26","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s40263-022-00954-w","volume":"36","author":"Y Winter","year":"2022","unstructured":"Winter Y, Sandner K, Vieth TL, Melzer N, Klimpe S, Meuth SG, et al. Eslicarbazepine acetate as adjunctive therapy for primary generalized tonic-clonic seizures in adults: a prospective observational study. CNS Drugs. 2022;36(10):1113\u20139.","journal-title":"CNS Drugs"},{"issue":"12","key":"1039_CR27","doi-asserted-by":"publisher","first-page":"763","DOI":"10.2165\/00003088-200443120-00001","volume":"43","author":"M Bialer","year":"2004","unstructured":"Bialer M, Doose DR, Murthy B, Curtin C, Wang SS, Twyman RE, et al. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet. 2004;43(12):763\u201380.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1039_CR28","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s40261-022-01241-8","volume":"43","author":"S Jing","year":"2023","unstructured":"Jing S, Shiba S, Morita M, Yasuda S, Lin Y. A single- and multiple-dose pharmacokinetic study of oral perampanel in healthy Chinese subjects. Clin Drug Investig. 2023;43(3):155\u201365.","journal-title":"Clin Drug Investig"},{"issue":"2","key":"1039_CR29","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/epd2.20004","volume":"25","author":"Y Winter","year":"2023","unstructured":"Winter Y, Sandner K, Vieth T, Groppa S. Eslicarbazepine acetate for the treatment of status epilepticus. Epileptic Disord. 2023;25(2):142\u20139.","journal-title":"Epileptic Disord"},{"issue":"9","key":"1039_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2330","volume":"11","author":"T Tanaka","year":"2021","unstructured":"Tanaka T, Fukuma K, Abe S, Matsubara S, Motoyama R, Mizobuchi M, et al. Antiseizure medications for post-stroke epilepsy: a real-world prospective cohort study. Brain Behav. 2021;11(9): e2330.","journal-title":"Brain Behav"},{"issue":"6","key":"1039_CR31","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/ane.13230","volume":"141","author":"F Rosenow","year":"2020","unstructured":"Rosenow F, Brandt C, Bozorg A, Dimova S, Steiniger-Brach B, Zhang Y, et al. Lacosamide in patients with epilepsy of cerebrovascular etiology. Acta Neurol Scand. 2020;141(6):473\u201382.","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"1039_CR32","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/phar.2229","volume":"39","author":"S Farrokh","year":"2019","unstructured":"Farrokh S, Bon J, Erdman M, Tesoro E. Use of newer anticonvulsants for the treatment of status epilepticus. Pharmacotherapy. 2019;39(3):297\u2013316.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"1039_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.seizure.2012.10.004","volume":"22","author":"J Mir\u00f3","year":"2013","unstructured":"Mir\u00f3 J, Toledo M, Santamarina E, Ricciardi AC, Villanueva V, Pato A, et al. Efficacy of intravenous lacosamide as an add-on treatment in refractory status epilepticus: a multicentric prospective study. Seizure. 2013;22(1):77\u20139.","journal-title":"Seizure."},{"issue":"2","key":"1039_CR34","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s12028-016-0322-2","volume":"26","author":"CR Newey","year":"2017","unstructured":"Newey CR, Le NM, Ahrens C, Sahota P, Hantus S. The safety and effectiveness of intravenous lacosamide for refractory status epilepticus in the critically ill. Neurocrit Care. 2017;26(2):273\u20139.","journal-title":"Neurocrit Care"},{"key":"1039_CR35","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.yebeh.2018.04.025","volume":"84","author":"E Santamarina","year":"2018","unstructured":"Santamarina E, Gonz\u00e1lez-Cuevas M, Toledo M, Jim\u00e9nez M, Becerra JL, Qu\u00edlez A, et al. Intravenous lacosamide (LCM) in status epilepticus (SE): weight-adjusted dose and efficacy. Epilepsy Behav. 2018;84:93\u20138.","journal-title":"Epilepsy Behav"},{"issue":"10","key":"1039_CR36","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1111\/j.1528-1167.2011.03204.x","volume":"52","author":"J H\u00f6fler","year":"2011","unstructured":"H\u00f6fler J, Unterberger I, Dobesberger J, Kuchukhidze G, Walser G, Trinka E. Intravenous lacosamide in status epilepticus and seizure clusters. Epilepsia. 2011;52(10):e148\u201352.","journal-title":"Epilepsia"},{"issue":"12","key":"1039_CR37","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1007\/s00415-013-7133-6","volume":"260","author":"E Santamarina","year":"2013","unstructured":"Santamarina E, Toledo M, Sueiras M, Raspall M, Ailouti N, Lainez E, et al. Usefulness of intravenous lacosamide in status epilepticus. J Neurol. 2013;260(12):3122\u20138.","journal-title":"J Neurol"},{"issue":"10","key":"1039_CR38","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.seizure.2013.07.011","volume":"22","author":"V Belcastro","year":"2013","unstructured":"Belcastro V, Vidale S, Pierguidi L, Sironi L, Tancredi L, Striano P, et al. Intravenous lacosamide as treatment option in post-stroke non convulsive status epilepticus in the elderly: a proof-of-concept, observational study. Seizure. 2013;22(10):905\u20137.","journal-title":"Seizure."},{"issue":"6","key":"1039_CR39","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/ane.13323","volume":"142","author":"F Sales","year":"2020","unstructured":"Sales F, Chaves J, McMurray R, Loureiro R, Fernandes H, Villanueva V. Eslicarbazepine acetate in post-stroke epilepsy: clinical practice evidence from Euro-Esli. Acta Neurol Scand. 2020;142(6):563\u201373.","journal-title":"Acta Neurol Scand"},{"issue":"Pt 2","key":"1039_CR40","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/brain\/awu339","volume":"138","author":"A Doeser","year":"2015","unstructured":"Doeser A, Dickhof G, Reitze M, Uebachs M, Schaub C, Pires NM, et al. Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug. Brain. 2015;138(Pt 2):371\u201387.","journal-title":"Brain"},{"issue":"18","key":"1039_CR41","doi-asserted-by":"publisher","first-page":"9737","DOI":"10.3390\/ijms22189737","volume":"22","author":"MJ Pawlik","year":"2021","unstructured":"Pawlik MJ, Miziak B, Walczak A, Konarzewska A, Chro\u015bci\u0144ska-Krawczyk M, Albrecht J, et al. Selected molecular targets for antiepileptogenesis. Int J Mol Sci. 2021;22(18):9737.","journal-title":"Int J Mol Sci."},{"issue":"6","key":"1039_CR42","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s00415-009-5053-2","volume":"256","author":"Y Winter","year":"2009","unstructured":"Winter Y, Wolfram C, Schaeg M, Reese JP, Oertel WH, Dodel R, et al. Evaluation of costs and outcome in cardioembolic stroke or TIA. J Neurol. 2009;256(6):954\u201363.","journal-title":"J Neurol"},{"issue":"2","key":"1039_CR43","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/j.1528-1167.2009.02268.x","volume":"51","author":"BA Dworetzky","year":"2010","unstructured":"Dworetzky BA, Bromfield EB, Townsend MK, Kang JH. A prospective study of smoking, caffeine, and alcohol as risk factors for seizures or epilepsy in young adult women: data from the Nurses\u2019 Health Study II. Epilepsia. 2010;51(2):198\u2013205.","journal-title":"Epilepsia"},{"key":"1039_CR44","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.yebeh.2019.01.041","volume":"93","author":"AL Johnson","year":"2019","unstructured":"Johnson AL, McLeish AC, Shear PK, Sheth A, Privitera M. The role of cigarette smoking in epilepsy severity and epilepsy-related quality of life. Epilepsy Behav. 2019;93:38\u201342.","journal-title":"Epilepsy Behav"},{"key":"1039_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.781174","volume":"13","author":"AR Tr\u00f6scher","year":"2021","unstructured":"Tr\u00f6scher AR, Gruber J, Wagner JN, B\u00f6hm V, Wahl AS, von Oertzen TJ. Inflammation mediated epileptogenesis as possible mechanism underlying ischemic post-stroke epilepsy. Front Aging Neurosci. 2021;13: 781174.","journal-title":"Front Aging Neurosci."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01039-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-023-01039-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01039-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T09:13:49Z","timestamp":1697102029000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-023-01039-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1039"],"URL":"https:\/\/doi.org\/10.1007\/s40263-023-01039-y","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"14 September 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by Projekt DEAL. Data collection in Marburg was supported by a research grant of the University Medical Center Giessen and Marburg.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Yaroslav Winter reports honoraria for educational presentations and consultations from Arvelle Therapeutics, Bayer AG, BIAL, Eisai, LivaNova, Novartis, and UCB Pharma. Sergiu Groppa received compensation for professional services from Abbott, Abbvie, Bial, Medtronic, UCB, and Zambon; research grants from Abbott, Boston Scientific, MagVenture, German Research Council, Innovations Fund, and the German Ministry of Education and Health. Katharina Sandner, Thomas Vieth, Gabriel Gonzalez-Escamilla, and Sebastian V. Stuckrad-Barre have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"This study was approved by the local ethics committee [State Medical Association Rheinland-Pfalz, Reference number: 837.560.17 (11394)].","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients signed an informed consent for participation in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization and design: YW, SG. Methodology and data collection: YW, KS, SSB, SG. Analysis and interpretation: YW, KS, TV, GGE, SG. Writing, original draft preparation: YW, KS, TV, SG. Writing, reviewing, and editing: YW, KS, TV, SSB, GGE, SG. All authors have read and approved the final submitted manuscript, and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}